Caribou Biosciences, Inc. last reported quarterly results on Aug 13, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $1.5 million (-43.8% year over year) and diluted EPS of -$0.24. It usually reports 34–64 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 2, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Monday. Based on last year's release for the same quarter on Nov 3, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 34–64 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 13, 2026
44 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1
-43.8%
|
-24
+55.1%
|
-0.24
+58.6%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
2
+1.9%
|
-25
+37.3%
|
-0.26
+39.5%
|
|
Mar 5, 2026
64 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
4
+89.7%
|
-26
+25.4%
|
-0.28
+28.0%
|
|
Nov 3, 2025
34 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
2
+8.6%
|
-28
+20.6%
|
-0.30
+21.1%
|
|
Aug 12, 2025
43 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
3
-23.0%
|
-54
-43.5%
|
-0.58
-38.1%
|
|
Apr 24, 2025
24 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
2
-3.1%
|
-40
+3.0%
|
-0.43
+6.5%
|
|
Mar 10, 2025
69 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
2
-41.6%
|
-35
-2.9%
|
-0.39
+0.3%
|
|
Nov 6, 2024
37 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
2
-91.4%
|
-35
-246.8%
|
-0.38
-216.7%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CRBU (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Berkeley, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1619856
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.